{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T05:12:02Z","timestamp":1737177122990,"version":"3.33.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,6,22]],"date-time":"2007-06-22T00:00:00Z","timestamp":1182470400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1007\/s11882-007-0044-9","type":"journal-article","created":{"date-parts":[[2007,6,21]],"date-time":"2007-06-21T09:17:07Z","timestamp":1182417427000},"page":"293-300","source":"Crossref","is-referenced-by-count":2,"title":["Current management options in myasthenia gravis"],"prefix":"10.1007","volume":"7","author":[{"given":"Stephen","family":"Reddel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,6,22]]},"reference":[{"key":"44_CR1","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM199406233302507","volume":"330","author":"D.B. Drachman","year":"1994","unstructured":"Drachman DB: Myasthenia gravis. N Engl J Med 1994, 330:1797\u20131810.","journal-title":"N Engl J Med"},{"key":"44_CR2","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/mus.20030","volume":"29","author":"J.C. Keesey","year":"2004","unstructured":"Keesey JC: Clinical evaluation and management of myasthenia gravis. Muscle Nerve 2004, 29:484\u2013505.","journal-title":"Muscle Nerve"},{"key":"44_CR3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1055\/s-2004-829594","volume":"24","author":"M.N. Meriggioli","year":"2004","unstructured":"Meriggioli MN, Sanders DB: Myasthenia gravis: diagnosis. Semin Neurol 2004, 24:31\u201339.","journal-title":"Semin Neurol"},{"key":"44_CR4","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/35097557","volume":"2","author":"J.R. Sanes","year":"2001","unstructured":"Sanes JR, Lichtman JW: Induction, assembly, maturation and maintenance of a postsynaptic apparatus. Nat Rev Neurosci 2001, 2:791\u2013805.","journal-title":"Nat Rev Neurosci"},{"key":"44_CR5","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.conb.2005.12.003","volume":"16","author":"T.T. Kummer","year":"2006","unstructured":"Kummer TT, Misgeld T, Sanes JR: Assembly of the postsynaptic membrane at the neuromuscular junction: paradigm lost. Curr Opin Neurobiol 2006, 16:74\u201382.","journal-title":"Curr Opin Neurobiol"},{"key":"44_CR6","doi-asserted-by":"crossref","DOI":"10.4324\/9780203302545","volume-title":"History of the Synapse","author":"M.R. Bennett","year":"2001","unstructured":"Bennett MR: History of the Synapse. New York: CRC; 2001."},{"key":"44_CR7","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1126\/science.1108258","volume":"308","author":"P. Escher","year":"2005","unstructured":"Escher P, Lacazette E, Courtet M, et al.: Synapses form in skeletal muscles lacking neuregulin receptors. Science 2005, 308:1920\u20131923.","journal-title":"Science"},{"key":"44_CR8","doi-asserted-by":"crossref","first-page":"11088","DOI":"10.1073\/pnas.0504806102","volume":"102","author":"T. Misgeld","year":"2005","unstructured":"Misgeld T, Kummer TT, Lichtman JW, Sanes JR: Agrin promotes synaptic differentiation by counteracting an inhibitory effect of neurotransmitter. Proc Natl Acad Sci U S A 2005, 102:11088\u201311093.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"44_CR9","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0092-8674(00)81252-0","volume":"85","author":"D.J. Glass","year":"1996","unstructured":"Glass DJ, Bowen DC, Stitt TN, et al.: Agrin acts via a MuSK receptor complex. Cell 1996, 85:513\u2013523.","journal-title":"Cell"},{"key":"44_CR10","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1126\/science.1127142","volume":"312","author":"K. Okada","year":"2006","unstructured":"Okada K, Inoue A, Okada M, et al.: The muscle protein Dok-7 is essential for neuromuscular synaptogenesis. Science 2006, 312:1802\u20131805.","journal-title":"Science"},{"key":"44_CR11","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/003693306000501001","volume":"5","author":"J.A. Simpson","year":"1960","unstructured":"Simpson JA: Myasthenia gravis: a new hypothesis. Scott Med J 1960, 5:419\u2013436.","journal-title":"Scott Med J"},{"key":"44_CR12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3181\/00379727-105-26050","volume":"105","author":"W.L. Nastuk","year":"1960","unstructured":"Nastuk WL, Plescia OJ, Osserman KE: Changes in serum complement activity in patients with myasthenia gravis. Proc Soc Exp Biol Med 1960, 105:177\u2013184.","journal-title":"Proc Soc Exp Biol Med"},{"key":"44_CR13","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1126\/science.180.4088.871","volume":"180","author":"J. Patrick","year":"1973","unstructured":"Patrick J, Lindstrom J: Autoimmune response to acetylcholine receptor. Science 1973, 180:871\u2013872.","journal-title":"Science"},{"key":"44_CR14","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","volume":"7","author":"W. Hoch","year":"2001","unstructured":"Hoch W, McConville J, Helms S, et al.: Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001, 7:365\u2013368.","journal-title":"Nat Med"},{"key":"44_CR15","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1126\/science.1179220","volume":"190","author":"K.V. Toyka","year":"1975","unstructured":"Toyka KV, Brachman DB, Pestronk A, Kao I: Myasthenia gravis: passive transfer from man to mouse. Science 1975, 190:397\u2013399.","journal-title":"Science"},{"key":"44_CR16","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0140-6736(76)91917-6","volume":"2","author":"A.J. Pinching","year":"1976","unstructured":"Pinching AJ, Peters DK: Remission of myasthenia gravis following plasma-exchange. Lancet 1976, 2:1373\u20131376.","journal-title":"Lancet"},{"key":"44_CR17","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/00005072-197609000-00008","volume":"35","author":"A.G. Engel","year":"1976","unstructured":"Engel AG, Tsujihata M, Lambert EH, et al.: Experimental autoimmune myasthenia gravis: a sequential and quantitative study of the neuromuscular junction ultrastructure and electrophysiologic correlations. J Neuropathol Exp Neurol 1976, 35:569\u2013587.","journal-title":"J Neuropathol Exp Neurol"},{"key":"44_CR18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1196\/annals.1254.026","volume":"998","author":"H. Shiono","year":"2003","unstructured":"Shiono H, Roxanis I, Zhang W, et al.: Scenarios for autoimmunization of T and B cells in myasthenia gravis. Ann N Y Acad Sci 2003, 998:237\u2013256.","journal-title":"Ann N Y Acad Sci"},{"key":"44_CR19","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/j.1749-6632.1981.tb33766.x","volume":"377","author":"H.J. Oosterhuis","year":"1981","unstructured":"Oosterhuis HJ: Observations of the natural history of myasthenia gravis and the effect of thymectomy. Ann N Y Acad Sci 1981, 377:678\u2013690.","journal-title":"Ann N Y Acad Sci"},{"key":"44_CR20","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1212\/WNL.57.11.2139","volume":"57","author":"G.D. Shelton","year":"2001","unstructured":"Shelton GD, Lindstrom JM: Spontaneous remission in canine myasthenia gravis: implications for assessing human MG therapies. Neurology 2001, 57:2139\u20132141.","journal-title":"Neurology"},{"key":"44_CR21","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ana.410140504","volume":"14","author":"C.T. Bever Jr","year":"1983","unstructured":"Bever CT Jr, Aquino AV, Penn AS, et al.: Prognosis of ocular myasthenia. Ann Neurol 1983, 14:516\u2013519.","journal-title":"Ann Neurol"},{"key":"44_CR22","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1749-6632.1987.tb51317.x","volume":"505","author":"D. Grob","year":"1987","unstructured":"Grob D, Arsura EL, Brunner NG, Namba T: The course of myasthenia gravis and therapies affecting outcome. Ann N Y Acad Sci 1987, 505:472\u2013499.","journal-title":"Ann N Y Acad Sci"},{"key":"44_CR23","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/jnnp.62.2.156","volume":"62","author":"N. Sommer","year":"1997","unstructured":"Sommer N, Sigg B, Melms A, et al.: Ocular myasthenia gravis: response to long-term immunosuppressive treatment. J Neurol Neurosurg Psychiatry 1997, 62:156\u2013162.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"44_CR24","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/archneur.60.2.243","volume":"60","author":"M.J. Kupersmith","year":"2003","unstructured":"Kupersmith MJ, Latkany R, Homel P: Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol 2003, 60:243\u2013248.","journal-title":"Arch Neurol"},{"key":"44_CR25","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00041327-200312000-00002","volume":"23","author":"J. Mee","year":"2003","unstructured":"Mee J, Paine M, Byrne E, et al.: Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J Neuroophthalmol 2003, 23:251\u2013255.","journal-title":"J Neuroophthalmol"},{"key":"44_CR26","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jns.2003.08.017","volume":"217","author":"N.T. Monsul","year":"2004","unstructured":"Monsul NT, Patwa HS, Knorr AM, et al.: The effect of prednisone on the progression from ocular to generalized myasthenia gravis. J Neurol Sci 2004, 217:131\u2013133.","journal-title":"J Neurol Sci"},{"key":"44_CR27","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1096\/fj.02-0609com","volume":"17","author":"T. Brenner","year":"2003","unstructured":"Brenner T, Hamra-Amitay Y, Evron T, et al.: The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis. FASEB J 2003, 17:214\u2013222.","journal-title":"FASEB J"},{"key":"44_CR28","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1126\/science.291.5503.484","volume":"291","author":"A. Samuelsson","year":"2001","unstructured":"Samuelsson A, Towers TL, Ravetch JV: Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001, 291:484\u2013486.","journal-title":"Science"},{"key":"44_CR29","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nm1416","volume":"12","author":"V. Siragam","year":"2006","unstructured":"Siragam V, Crow AR, Brinc D, et al.: Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat Med 2006, 12:688\u2013692.","journal-title":"Nat Med"},{"key":"44_CR30","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ana.410150316","volume":"15","author":"R.M. Pascuzzi","year":"1984","unstructured":"Pascuzzi RM, Coslett HB, Johns TR: Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 1984, 15:291\u2013298.","journal-title":"Ann Neurol"},{"key":"44_CR31","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","volume":"50","author":"J. Palace","year":"1998","unstructured":"Palace J, Newsom-Davis J, Lecky B: A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 1998, 50:1778\u20131783.","journal-title":"Neurology"},{"key":"44_CR32","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1399-0012.1996.tb00651.x","volume":"10","author":"A.C. Allison","year":"1996","unstructured":"Allison AC, Eugui EM: Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 1996, 10:77\u201384.","journal-title":"Clin Transplant"},{"key":"44_CR33","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1212\/01.WNL.0000094122.88929.0B","volume":"61","author":"M.N. Meriggioli","year":"2003","unstructured":"Meriggioli MN, Ciafaloni E, Al Hayk KA, et al.: Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 2003, 61:1438\u20131440.","journal-title":"Neurology"},{"key":"44_CR34","unstructured":"Aspreva Pharmaceuticals: Mycophenolate mofetil. Available at: http:\/\/www.aspreva.com\/clinical_trials.php#mg . Accessed March 20, 2007."},{"key":"44_CR35","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1749-6632.1993.tb22937.x","volume":"681","author":"R.S. Tindall","year":"1993","unstructured":"Tindall RS, Phillips JT, Rollins JA, et al.: A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci 1993, 681:539\u2013551.","journal-title":"Ann N Y Acad Sci"},{"key":"44_CR36","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1212\/01.WNL.0000160392.32894.6D","volume":"64","author":"J.M. Ponseti","year":"2005","unstructured":"Ponseti JM, Azem J, Fort JM, et al.: Long-term results of tacrolimus in cyclosporine-and prednisone-dependent myasthenia gravis. Neurology 2005, 64:1641\u20131643.","journal-title":"Neurology"},{"key":"44_CR37","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mus.10133","volume":"26","author":"L.G. Feo De","year":"2002","unstructured":"De Feo LG, Schottlender J, Martelli NA, Molfino NA: Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. Muscle Nerve 2002, 26:31\u201336.","journal-title":"Muscle Nerve"},{"key":"44_CR38","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ana.10400","volume":"53","author":"D.B. Drachman","year":"2003","unstructured":"Drachman DB, Jones RJ, Brodsky RA: Treatment of refractory myasthenia: \u201crebooting\u201d with high-dose cyclophosphamide. Ann Neurol 2003, 53:29\u201334.","journal-title":"Ann Neurol"},{"key":"44_CR39","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","volume":"6","author":"M.D. Pescovitz","year":"2006","unstructured":"Pescovitz MD: Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006, 6:859\u2013866.","journal-title":"Am J Transplant"},{"key":"44_CR40","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1212\/WNL.55.1.7","volume":"55","author":"G.S. Gronseth","year":"2000","unstructured":"Gronseth GS, Barohn RJ: Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000, 55:7\u201315.","journal-title":"Neurology"},{"key":"44_CR41","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1055\/s-2004-829596","volume":"24","author":"A. Jaretzki","year":"2004","unstructured":"Jaretzki A, Steinglass KM, Sonett JR: Thymectomy in the management of myasthenia gravis. Semin Neurol 2004, 24:49\u201362.","journal-title":"Semin Neurol"},{"key":"44_CR42","unstructured":"National Institute of Neurological Disorders and Stroke: A multi-center, single-blind, randomized study comparing thymectomy to no thymectomy in non-thymomatous myasthenia gravis (MG) patients receiving prednisone. Available at: http:\/\/clinicaltrials.gov\/ct\/show\/NCT00294658 . Accessed March 20, 2007."},{"key":"44_CR43","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1359\/jbmr.2003.18.5.919","volume":"18","author":"P.N. Sambrook","year":"2003","unstructured":"Sambrook PN, Kotowicz M, Nash P, et al.: Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 2003, 18:919\u2013924.","journal-title":"J Bone Miner Res"},{"key":"44_CR44","first-page":"317","volume":"45","author":"J.D. Baxter","year":"2000","unstructured":"Baxter JD: Advances in glucocorticoid therapy. Adv Intern Med 2000, 45:317\u2013349.","journal-title":"Adv Intern Med"},{"key":"44_CR45","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0022-510X(99)00205-1","volume":"170","author":"J.C. Keesey","year":"1999","unstructured":"Keesey JC: Does myasthenia gravis affect the brain? J Neurol Sci 1999, 170:77\u201389.","journal-title":"J Neurol Sci"},{"key":"44_CR46","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0165-5728(96)00144-0","volume":"71","author":"S.J. Piddlesden","year":"1996","unstructured":"Piddlesden SJ, Jiang S, Levin JL, et al.: Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis. J Neuroimmunol 1996, 71:173\u2013177.","journal-title":"J Neuroimmunol"},{"key":"44_CR47","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1006\/clim.1999.4807","volume":"94","author":"P. Christadoss","year":"2000","unstructured":"Christadoss P, Poussin M, Deng C: Animal models of myasthenia gravis. Clin Immunol 2000, 94:75\u201387.","journal-title":"Clin Immunol"},{"key":"44_CR48","doi-asserted-by":"crossref","first-page":"12642","DOI":"10.1073\/pnas.221456798","volume":"98","author":"M. Paas-Rozner","year":"2001","unstructured":"Paas-Rozner M, Sela M, Mozes E: The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes. Proc Natl Acad Sci U S A 2001, 98:12642\u201312647.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"44_CR49","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1046\/j.1365-2249.2002.01748.x","volume":"127","author":"D. Yarilin","year":"2002","unstructured":"Yarilin D, Duan R, Huang YM, Xiao BG: Dendritic cells exposed in vitro to TGF-beta1 ameliorate experimental autoimmune myasthenia gravis. Clin Exp Immunol 2002, 127:214\u2013219.","journal-title":"Clin Exp Immunol"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-007-0044-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11882-007-0044-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-007-0044-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T11:18:32Z","timestamp":1737112712000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11882-007-0044-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,22]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["44"],"URL":"https:\/\/doi.org\/10.1007\/s11882-007-0044-9","relation":{},"ISSN":["1529-7322","1534-6315"],"issn-type":[{"type":"print","value":"1529-7322"},{"type":"electronic","value":"1534-6315"}],"subject":[],"published":{"date-parts":[[2007,6,22]]}}}